Terminology

Frable, William J.; Austin, R. Marshall; Greening, Shirley E.; Collins, Robert J.; Hillman, Roger L.; Kobler, Terry Paul; Lg, Koss; Mitchell, Heather; Perey, R; Rosenthal, Dorothy L.; Sidoti, Mark S.; Somrak, Theresa M.

doi:10.1159/000331529

Cited by 27 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2, row 1). Among group II findings ("findings with limited protective value", II-p, II-g, II-e) [9], with a combined rate of 1.061%, marginal squamous epithelial changes (II-p ≙ ASC-US) are predominant at 0.814%.…”

Section: Cytological Diagnostic Groups According To the Munich Nomenc...mentioning

confidence: 99%

“…2, Zeile 1). Unter den Befunden der Gruppe II ("Befunde mit eingeschränkt protektivem Wert", II-p, II-g, II-e) [9], zusammen 1,061%, dominieren die marginalen plattenepithelialen Veränderungen (II-p ≙ ASC-US) mit 0,814%. Unter den auffälligen Befunden überwiegen Fälle, die 2019 keine unmittelbaren Maßnahmen, außer z.…”

Section: Zytologische Diagnosegruppen Nach Der Münchner Nomenklatur IIIunclassified

“…"Befunde mit eingeschränkt protektivem Wert" [9]: Der Anteil der histologischen Untersuchungen bei II-p bis II-e lag zwischen 1,09% für II-p und 1,47% für II-e. Bei II-g betrug der Anteil der "Klärungen" 1,17%.…”

Section: Anteil Histologischer Untersuchungen In Den Zytologischen Be...unclassified

“…"Findings with limited protective value" [9]: The proportion of histological examinations for II-p to II-e ranged from 1.09% for II-p to 1.47% for II-e. For II-g, the proportion of "histological clarifications" was 1.17%. However, there is no consistent ascending risk trend among the Munich Nomenclature III diagnostic groups I to V. Group III with the unclear/doubtful findings is arbitrarily placed ahead of the groups of findings with the expectation of clearly definable histology, i.e., before groups IIID1 to V-x.…”

Section: Proportion Of Histological Examinations In the Cytology Groupsmentioning

confidence: 99%

See 3 more Smart Citations

Evaluations of the 2019 Annual Statistics Under the Cervical Cytology Quality Assurance Agreement

Schenck,

Hantschke-Zerbich,

Woellner

et al. 2023

Geburtshilfe Frauenheilkd

Self Cite

View full text Add to dashboard Cite

Cervical cancer screening, which was introduced into the programme of medical care covered by statutory health insurance in Germany in 1971 and has since been constantly updated through quality assurance measures, was fundamentally revised and developed in 2008 through the Cervical Cytology Quality Assurance Agreement pursuant to Section 135(2) of the German Social Code Book V [SGB V]. Since 2015 it has been mandatory for cytology facilities to record annual statistics based on the Munich Nomenclature III. The aim of this article is to present the results of the annual statistics for 2019, which was the last year before the introduction of the cervical cancer screening programme in accordance with the Federal Joint Committee’s guideline on organised cancer screening programmes 1.The annual statistics of the laboratories, including histology analyses performed up until 30 June the following year, are reported to the Regional Associations of Statutory Health Insurance Physicians. The laboratories receive benchmark reports from their Regional Associations of Statutory Health Insurance Physicians, and these statistics are transmitted anonymously to the National Association of Statutory Health Insurance Physicians (KBV).In 2019, 17609082 smears from 15608413 women were examined in Germany. Of these smears, 97.49% were normal and 2.51% showed atypical or suspicious changes, consisting mostly of minor squamous epithelial changes in groups II-p (0.81%) and IIID1 (0.735%).Histology specimens are available for “Dysplasia findings with higher probability of regression” in group IIID1 (4.89% of initial IIID1 cytology findings), group IIID2 (18.60%), “unclear or doubtful findings” in group III-p to x (20.7%), and “immediate precursors to cervical carcinoma” in group IV (83.1%) and group V (77.19%).In the cytology findings for group IVa-p, which corresponds to CIN 3 target lesions, the cytology correlated with the histology finding in 80.48% of cases.Lesions found in 2019: 23463 CIN 3 lesions, 668 adenocarcinomas in situ, 3891 malignant tumours, including 2342 cervical carcinomas of which 1743 were squamous cell carcinomas and 599 were cervical adenocarcinomas (25.57%); 1549 endometrial carcinomas and other malignancies.The data demonstrate the good practicability of cervical cancer screening in 2019. Higher grade lesions were reliably clarified histologically.

show abstract

Section: Cytological Diagnostic Groups According To the Munich Nomenc...mentioning

confidence: 99%

Section: Zytologische Diagnosegruppen Nach Der Münchner Nomenklatur IIIunclassified

Section: Anteil Histologischer Untersuchungen In Den Zytologischen Be...unclassified

Section: Proportion Of Histological Examinations In the Cytology Groupsmentioning

confidence: 99%

See 2 more Smart Citations

Evaluations of the 2019 Annual Statistics Under the Cervical Cytology Quality Assurance Agreement

Schenck,

Hantschke-Zerbich,

Woellner

et al. 2023

Geburtshilfe Frauenheilkd

Self Cite

View full text Add to dashboard Cite

show abstract

“…Management of PT by a body not linked to any particular laboratory or institution and operating as a form of professional self-regulation rather than being imposed by a regulatory authority. Given the documented difficulties in adopting a uniform terminology and diagnostic classification worldwide, 21 at no time was terminology an issue. In both countries professionals are familiar with the 28 Acta Cytologica 22 (translated into Spanish) to start with since the slides borrowed from the Scottish scheme had been diagnosed using this reporting system.…”

Section: Discussionmentioning

confidence: 99%

External Quality Assurance for Cervical Cytology in Developing Countries

Salvetto¹,

Sandiford²

2004

Acta Cytologica

View full text Add to dashboard Cite

DNA cytometry confirms the utility of the Bethesda system for the classification of Papanicolaou smears

Bollmann¹,

Bollmann²,

Henson

et al. 2001

Cancer

View full text Add to dashboard Cite

BACKGROUND Developed in 1989, the Bethesda System has largely replaced previous classifications of Papanicolaou (Pap) smears from the uterine cervix. The system is binary, dividing smears into two groups — low‐grade, squamous, epithelial lesions (LSIL) or high‐grade, squamous, epithelial lesions (HSIL). A third category, atypical squamous cells of undetermined significance (ASCUS), is used to classify minimal cellular changes that do not satisfy the criteria for the low‐ or high‐grade categories. This study was designed to confirm the utility of this binary division and to compare the results with another classification system (the Munich II Nomenclature) that is not binary but contains three divisions or grades for dysplasia — low, intermediate, and high. METHODS Pap smears were obtained from 593 women with a cytologic diagnosis of dysplasia based on the Munich System. Smears were then classified by the Bethesda System into LSIL or HSIL. Patients were followed for 2 years either with biopsy or repeat cytology. The initial smears were restained by the Feulgen method, and ploidy was evaluated by interactive DNA cytometry. RESULTS Of 241 cases of LSIL, 39% were diploid, 57% polyploid, and 4% aneuploid. Of 352 cases classified HSIL, 4% were diploid, 17% polyploid, and 79% aneuploid. After 2 years of follow‐up, 2 of 108 patients who were biopsied and who were originally classified as diploid progressed to cervical intraepithelial neoplasia/carcinoma in situ (CIN/CIS) whereas 109 of 217 patients who were aneuploid and biopsied were found to have CINIII/CIS. CONCLUSIONS The two divisions of the Bethesda System, LSIL and HSIL, correlated with ploidy as evaluated by cytometry. Aneuploidy was found to be useful to separate cases of HSIL from those of LSIL as defined in the Bethesda System. Because of the binary division, use of a system with three divisions for dysplasia, such as the Munich II Nomenclature, creates a therapeutic dilemma because a single diagnostic category (usually the intermediate grade) may contain both self‐limiting and progressive lesions. DNA cytometry of Pap smears was found to be useful as a routine procedure. Cancer (Cancer Cytopathol) 2001;93:222–228. © 2001 American Cancer Society.

show abstract

Terminology

Cited by 27 publications

References 4 publications

Evaluations of the 2019 Annual Statistics Under the Cervical Cytology Quality Assurance Agreement

Evaluations of the 2019 Annual Statistics Under the Cervical Cytology Quality Assurance Agreement

External Quality Assurance for Cervical Cytology in Developing Countries

DNA cytometry confirms the utility of the Bethesda system for the classification of Papanicolaou smears

Contact Info

Product

Resources

About